A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).

MLA

Wrzesień-Kuś, A., et al. “A Multicenter, Open, Non-Comparative, Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia - a Report of the Polish Adult Leukemia Group (PALG).” European Journal of Haematology, vol. 71, no. 3, Sept. 2003, pp. 155–62. EBSCOhost, https://doi.org/10.1034/j.1600-0609.2003.00122.x.

APA

Wrzesień-Kuś, A., Robak, T., Lech-Marańda, E., Wierzbowska, A., Dmoszyńska, A., Kowal, M., Hołowiecki, J., Kyrcz-Krzemień, S., Grosicki, S., Maj, S., Hellmann, A., Skotnicki, A., Jedrzejczak, W., & Kuliczkowski, K. (2003). A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). European Journal of Haematology, 71(3), 155–162. https://doi.org/10.1034/j.1600-0609.2003.00122.x

Chicago

Wrzesień-Kuś, A, T Robak, E Lech-Marańda, A Wierzbowska, A Dmoszyńska, M Kowal, J Hołowiecki, et al. 2003. “A Multicenter, Open, Non-Comparative, Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia - a Report of the Polish Adult Leukemia Group (PALG).” European Journal of Haematology 71 (3): 155–62. doi:10.1034/j.1600-0609.2003.00122.x.